Techno Drugs Statistics

Total Valuation

Techno Drugs has a market cap or net worth of BDT 3.84 billion. The enterprise value is 6.11 billion.

Market Cap	3.84B
Enterprise Value	6.11B

Important Dates

The next estimated earnings date is Thursday, January 29, 2026.

Earnings Date	Jan 29, 2026
Ex-Dividend Date	Nov 20, 2025

Share Statistics

Techno Drugs has 132.00 million shares outstanding. The number of shares has increased by 31.22% in one year.

Current Share Class	132.00M
Shares Outstanding	132.00M
Shares Change (YoY)	+31.22%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	66.79%
Owned by Institutions (%)	n/a
Float	37.84M

Valuation Ratios

The trailing PE ratio is 16.14.

PE Ratio	16.14
Forward PE	n/a
PS Ratio	1.23
PB Ratio	0.96
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	22.47
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.41, with an EV/FCF ratio of -9.97.

EV / Earnings	27.42
EV / Sales	1.95
EV / EBITDA	6.41
EV / EBIT	10.57
EV / FCF	-9.97

Financial Position

The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.68.

Current Ratio	2.17
Quick Ratio	1.02
Debt / Equity	0.68
Debt / EBITDA	2.83
Debt / FCF	-4.40
Interest Coverage	1.76

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	10.06%
Revenue Per Employee	1.85M
Profits Per Employee	131,467
Employee Count	1,694
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Techno Drugs has paid 27.56 million in taxes.

Income Tax	27.56M
Effective Tax Rate	11.01%

Stock Price Statistics

The stock price has decreased by -25.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.38%
50-Day Moving Average	32.24
200-Day Moving Average	31.89
Relative Strength Index (RSI)	42.37
Average Volume (20 Days)	753,098

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Techno Drugs had revenue of BDT 3.13 billion and earned 222.71 million in profits. Earnings per share was 1.80.

Revenue	3.13B
Gross Profit	1.30B
Operating Income	577.51M
Pretax Income	250.26M
Net Income	222.71M
EBITDA	925.89M
EBIT	577.51M
Earnings Per Share (EPS)	1.80

Full Income Statement

Balance Sheet

The company has 405.40 million in cash and 2.69 billion in debt, giving a net cash position of -2.29 billion or -17.34 per share.

Cash & Cash Equivalents	405.40M
Total Debt	2.69B
Net Cash	-2.29B
Net Cash Per Share	-17.34
Equity (Book Value)	3.99B
Book Value Per Share	30.24
Working Capital	1.85B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 170.98 million and capital expenditures -783.71 million, giving a free cash flow of -612.73 million.

Operating Cash Flow	170.98M
Capital Expenditures	-783.71M
Free Cash Flow	-612.73M
FCF Per Share	-4.64

Full Cash Flow Statement

Margins

Gross margin is 41.50%, with operating and profit margins of 18.47% and 7.12%.

Gross Margin	41.50%
Operating Margin	18.47%
Pretax Margin	8.00%
Profit Margin	7.12%
EBITDA Margin	29.61%
EBIT Margin	18.47%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 4.12%.

Dividend Per Share	1.20
Dividend Yield	4.12%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	22.18%
Buyback Yield	-31.22%
Shareholder Yield	-27.10%
Earnings Yield	5.80%
FCF Yield	-15.95%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Techno Drugs has an Altman Z-Score of 2.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.09
Piotroski F-Score	3